HealthInvest Partners’s Supernus Pharmaceuticals SUPN Stock Holding History

HealthInvest Partners’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-335,000	Closed	-$8.93M	–	17
2021 Q3	$8.93M	Sell	335,000 -195,000	-37%	-$5.23M	13.38%	2
2021 Q2	$16.3M	Sell	530,000 -4,000	-0.7%	-$123K	15.46%	2
2021 Q1	$14M	Buy	534,000 +69,000	+15%	+$1.93M	11.13%	2
2020 Q4	$11.7M	Buy	+465,000	New	+$10M	7.75%	1
2017 Q1	–	Sell	-538,241	Closed	-$13.6M	–	15
2016 Q4	$13.6M	Buy	538,241 +158,708	+42%	+$3.55M	12.52%	1
2016 Q3	$9.39M	Sell	379,533 -278,000	-42%	-$6.29M	6.98%	11
2016 Q2	$13.4M	Sell	657,533 -246,000	-27%	-$4.36M	6.14%	4
2016 Q1	$13.8M	Sell	903,533 -147,744	-14%	-$1.93M	6.45%	6
2015 Q4	$14.1M	Buy	1,051,277 +268,531	+34%	+$4.15M	6.65%	12
2015 Q3	$11M	Buy	+782,746	New	+$14.6M	6.5%	9

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

HealthInvest Partners's SUPN Position: Q4 2021 in Review

HealthInvest Partners sold out of Supernus Pharmaceuticals (SUPN) in Q4 2021, closing a stake of 335,000 shares — an estimated $8.93M sold.

HealthInvest Partners first reported a position in SUPN in Q3 2015 and held it in 10 quarters. The position peaked at $16.3M in Q2 2021. 235 funds tracked by Wall St. Rank hold SUPN as of Q4 2021.

HealthInvest Partners reported no remaining Supernus Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
HealthInvest Partners sold 335,000 Supernus Pharmaceuticals shares in Q4 2021, an estimated $8.93M.
HealthInvest Partners first reported a position in Supernus Pharmaceuticals in Q3 2015 and held it in 10 quarters.
HealthInvest Partners's Supernus Pharmaceuticals position peaked at $16.3M in Q2 2021.
235 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2021.

Based on HealthInvest Partners's 13F filing for Q4 2021, filed 18 Jan 2022.